Concord Biotech Bilan de santé
Santé financière contrôle des critères 5/6
Concord Biotech has a total shareholder equity of ₹15.3B and total debt of ₹97.4M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹17.0B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.0B making its interest coverage ratio -395.1. It has cash and short-term investments of ₹2.8B.
Informations clés
0.6%
Ratio d'endettement
₹97.38m
Dette
| Ratio de couverture des intérêts | -395.1x |
| Argent liquide | ₹2.82b |
| Fonds propres | ₹15.27b |
| Total du passif | ₹1.74b |
| Total des actifs | ₹17.01b |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: CONCORDBIO's short term assets (₹9.0B) exceed its short term liabilities (₹1.4B).
Passif à long terme: CONCORDBIO's short term assets (₹9.0B) exceed its long term liabilities (₹319.1M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: CONCORDBIO has more cash than its total debt.
Réduire la dette: Insufficient data to determine if CONCORDBIO's debt to equity ratio has reduced over the past 5 years.
Couverture de la dette: CONCORDBIO's debt is well covered by operating cash flow (2726.2%).
Couverture des intérêts: CONCORDBIO earns more interest than it pays, so coverage of interest payments is not a concern.